JP2008511607A - 低溶解性薬物および重合体を含む医薬投与剤形 - Google Patents

低溶解性薬物および重合体を含む医薬投与剤形 Download PDF

Info

Publication number
JP2008511607A
JP2008511607A JP2007529031A JP2007529031A JP2008511607A JP 2008511607 A JP2008511607 A JP 2008511607A JP 2007529031 A JP2007529031 A JP 2007529031A JP 2007529031 A JP2007529031 A JP 2007529031A JP 2008511607 A JP2008511607 A JP 2008511607A
Authority
JP
Japan
Prior art keywords
drug
polymer
solubility
precipitation
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007529031A
Other languages
English (en)
Japanese (ja)
Inventor
リーア・エリザベス・アッペル
ウォルター・クリスティアン・バブコック
ドウェイン・トマス・フリーゼン
ロデリック・ジャック・レイ
シェリ・リン・シャンブリン
ラヴィ・マイソーア・シャンカー
ダニエル・トッド・スミジー
Original Assignee
ファイザー・プロダクツ・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・プロダクツ・インク filed Critical ファイザー・プロダクツ・インク
Publication of JP2008511607A publication Critical patent/JP2008511607A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2007529031A 2004-08-31 2005-08-18 低溶解性薬物および重合体を含む医薬投与剤形 Pending JP2008511607A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60617804P 2004-08-31 2004-08-31
PCT/IB2005/002704 WO2006024944A2 (en) 2004-08-31 2005-08-18 Pharmaceutical dosage forms comprising a low-solubility drug and a polymer

Publications (1)

Publication Number Publication Date
JP2008511607A true JP2008511607A (ja) 2008-04-17

Family

ID=35705238

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007529031A Pending JP2008511607A (ja) 2004-08-31 2005-08-18 低溶解性薬物および重合体を含む医薬投与剤形

Country Status (14)

Country Link
US (2) US20090142404A1 (no)
EP (1) EP1789020A2 (no)
JP (1) JP2008511607A (no)
KR (1) KR20070046892A (no)
CN (1) CN101123951A (no)
AU (1) AU2005278894A1 (no)
BR (1) BRPI0514753A (no)
CA (1) CA2577852A1 (no)
IL (1) IL181197A0 (no)
MX (1) MX2007002378A (no)
NO (1) NO20070779L (no)
RU (1) RU2007106036A (no)
WO (1) WO2006024944A2 (no)
ZA (1) ZA200701059B (no)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012530125A (ja) * 2009-06-19 2012-11-29 ナノフォーム ハンガリー リミテッド ナノ構造のシルデナフィル塩基、薬学的に許容されるその塩及び共結晶、それらの組成物、その調製方法、並びにそれらを含有する医薬組成物

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101123951A (zh) 2004-08-31 2008-02-13 辉瑞产品公司 包括低溶解性药物和聚合物的药物剂型
WO2010082855A1 (en) * 2009-01-15 2010-07-22 Zaklady Farmaceutyczne Polpharma Sa Pharmaceutical compositions comprising ziprasidone free base or ziprasidone hydrochloride and the method for their preparation
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
US20130108701A1 (en) 2010-05-25 2013-05-02 Krishna Murthy Bhavanasi Solid Dosage Forms of Antipsychotics
CN102139115B (zh) * 2011-03-30 2012-12-05 天津红日药业股份有限公司 阿托伐他汀的环糊精包合物及其口服固体制剂的制备方法
CA2962719A1 (en) 2014-10-31 2016-05-06 Bend Research Inc. Process for forming active domains dispersed in a matrix
CN107303278B (zh) * 2016-04-25 2020-11-13 成都海创药业有限公司 一种hc-1119固体分散体及其制备方法
TWI631985B (zh) * 2016-10-26 2018-08-11 財團法人金屬工業研究發展中心 微粒製造方法
WO2019128991A1 (en) * 2017-12-26 2019-07-04 Sunshine Lake Pharma Co., Ltd. Lurasidone solid dispersion and preparation method thereof
US11708463B2 (en) 2018-04-06 2023-07-25 Capsugel Belgium Nv Spray drying process for low aspect ratio particles comprising poly[(methyl methacrylate)-co-(methacrylic acid)]
CN111728953B (zh) * 2020-07-29 2023-08-08 中国科学院上海药物研究所 一种托法替布或其盐的缓释制剂及其制备方法
WO2022081310A2 (en) * 2020-09-22 2022-04-21 Michael Ogburn Inhaled pde-v inhibitor drugs

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11116502A (ja) * 1997-08-11 1999-04-27 Pfizer Prod Inc 噴霧乾燥固体分散系を含む組成物
WO2003000226A2 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
JP2003026607A (ja) * 2001-06-22 2003-01-29 Pfizer Prod Inc 薬剤と濃度を高めるポリマーとを含む医薬組成物
JP2003518485A (ja) * 1999-12-23 2003-06-10 ファイザー・プロダクツ・インク 向上された薬物濃度を与える医薬組成物
WO2004014342A1 (en) * 2002-08-12 2004-02-19 Pfizer Products Inc. Pharmaceutical compositions of semi-ordered drugs and polymers

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5277916A (en) * 1988-02-01 1994-01-11 F. H. Faulding & Co., Ltd. Tetracycline dosage form
US20030064108A1 (en) * 1996-04-23 2003-04-03 Stefan Lukas Taste masked pharmaceutical compositions
AUPN969796A0 (en) * 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
GB9718986D0 (en) 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
US6165506A (en) * 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
EP1970052A2 (en) * 1999-02-09 2008-09-17 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability
DE60039802D1 (de) * 1999-02-10 2008-09-25 Pfizer Prod Inc Vorrichtung mit matrixgesteuerter Wirkstofffreisetzung
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
WO2002043704A1 (en) 2000-12-01 2002-06-06 Kyowa Hakko Kogyo Co., Ltd. Composition improved in solubility or oral absorbability
HUP0400281A3 (en) * 2001-06-22 2009-11-30 Pfizer Prod Inc Pharmaceutical compositions of adsorbates of amorphous drug and process for their preparation
SE0103839D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
JP2005523262A (ja) * 2002-02-01 2005-08-04 ファイザー・プロダクツ・インク 薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物
BRPI0414082A (pt) * 2003-09-02 2006-10-24 Pfizer Prod Inc formas de dosagem de liberação sustentada de ziprasidona
BRPI0417338A (pt) * 2003-12-04 2007-04-17 Pfizer Prod Inc formas de dosagem de azitromicina multiparticulada por processos a base de lìquido
CA2552126A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Ziprasidone formulations
CA2551254A1 (en) * 2003-12-31 2005-07-21 Pfizer Products Inc. Stabilized pharmaceutical solid compositions of low-solubility drugs, poloxamers, and stabilizing polymers
CA2471219A1 (en) * 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
CN101123951A (zh) 2004-08-31 2008-02-13 辉瑞产品公司 包括低溶解性药物和聚合物的药物剂型
MX2009011681A (es) * 2007-05-18 2009-11-10 Scidose Llc Formulaciones de ziprasidona.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11116502A (ja) * 1997-08-11 1999-04-27 Pfizer Prod Inc 噴霧乾燥固体分散系を含む組成物
JP2003518485A (ja) * 1999-12-23 2003-06-10 ファイザー・プロダクツ・インク 向上された薬物濃度を与える医薬組成物
WO2003000226A2 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
JP2003026607A (ja) * 2001-06-22 2003-01-29 Pfizer Prod Inc 薬剤と濃度を高めるポリマーとを含む医薬組成物
WO2004014342A1 (en) * 2002-08-12 2004-02-19 Pfizer Products Inc. Pharmaceutical compositions of semi-ordered drugs and polymers

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012530125A (ja) * 2009-06-19 2012-11-29 ナノフォーム ハンガリー リミテッド ナノ構造のシルデナフィル塩基、薬学的に許容されるその塩及び共結晶、それらの組成物、その調製方法、並びにそれらを含有する医薬組成物

Also Published As

Publication number Publication date
ZA200701059B (en) 2008-08-27
US20150064264A1 (en) 2015-03-05
RU2007106036A (ru) 2008-10-10
CN101123951A (zh) 2008-02-13
EP1789020A2 (en) 2007-05-30
IL181197A0 (en) 2007-07-04
AU2005278894A1 (en) 2006-03-09
WO2006024944A2 (en) 2006-03-09
WO2006024944A3 (en) 2006-08-24
BRPI0514753A (pt) 2008-06-24
MX2007002378A (es) 2007-04-23
KR20070046892A (ko) 2007-05-03
US9445998B2 (en) 2016-09-20
NO20070779L (no) 2007-03-08
US20090142404A1 (en) 2009-06-04
CA2577852A1 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
US9445998B2 (en) Pharmaceutical dosage forms comprising a low-solubility drug and a polymer
CA2298245C (en) Matrix controlled release device
US10383941B2 (en) Spray drying processes for forming solid amorphous dispersions of drugs and polymers
AU2013315619B2 (en) Formulations of enzalutamide
US8501231B2 (en) Pharmaceutical compositions providing enhanced drug concentrations
US6973741B2 (en) Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
US20100003331A1 (en) Sustained release dosage forms of ziprasidone
US20080064763A1 (en) Pharmaceutical Compositions with Enhanced Performance
JP2005523260A (ja) 圧力ノズルを用いた均質噴霧乾燥固体非晶質薬剤分散体の製造方法
US20080299188A1 (en) Controlled release dosage forms combining immediate release and sustainted release of low-solubility drug
JP2005517690A (ja) 固体薬物分散物を含有する即時放出剤形
JP2007517015A (ja) 低溶解性薬物、ポロキサマーおよび安定化ポリマーの安定化された医薬用固体組成物
JP2008511609A (ja) 低−溶解性薬物の速放及び徐放を組み合わせた制御放出型投薬形態
Pawar et al. RECENT DEVELOPMENT AND ACHIEVEMENTS IN SOLUBILITY AND DISSOLUTION ENHANCEMENT OF ITRACONAZOLE: A REVIEW
MXPA00001417A (en) Matrix controlled release device

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110524

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111220